Os"meus" titulos para a semana: SEGUNDO >>

[Luka!]

Alias isto na nossa praça está dificil é apanhar titulos que tenham potencial de subida.

... também podes olhar para o outro lado do Atlantico...

:arrow: XOMA waiting for March 4 ... after Conference presentations usually good UPSIDE momentum.

Press Release Source: XOMA Ltd.


XOMA to Present At Susquehanna Financial Group Healthcare Conference On March 4Wednesday February 27, 4:35 pm ET


BERKELEY, Calif., Feb. 27, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (NasdaqGM:XOMA - News), a leader in the discovery and development of antibody therapeutics, announced today that Steven Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference. The presentation will take place in New York on Tuesday, March 4, 2008 at 3:00 p.m. Eastern time.
An audio webcast of the presentation will be available live on the XOMA website at http://www.xoma.com. An archived version of the webcast will be available on the XOMA website for 90 days following the presentation.

About XOMA

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. The Company's expanding pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 629, a synthetic peptide compound derived from bactericidal/permeability-increasing protein.

XOMA's proprietary development pipeline is primarily funded by multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations, and biodefense contracts. XOMA's technologies and experienced team have contributed to the success of marketed antibody products, including RAPTIVA(r) (efalizumab) for chronic moderate to severe plaque psoriasis and LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration.

The Company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression (BCE) technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses.

In addition to developing its own products, XOMA develops products for premier pharmaceutical companies including Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to product launch, and a team of 300 employees at its Berkeley location. For more information, please visit http://www.xoma.com.

[Luka!]

XOMA - fundamentals & technicals (buy point) >>

FUNDAMENTALS >>>(Zacks.com )

Our Bull of the Day recommendation is for Xoma, Ltd. (Nasdaq: XOMA). Sales of all products that Xoma receives a royalty on have been reported by collaboration partners. We are expected total royalty revenues for the fourth quarter 2007 of $4.9 million. This is up slightly from our previous forecast of $4.7 million thanks to stronger international sales of both Raptiva and Lucentis. Xoma is expected to report fourth quarter results on March 11, 2008. We are forecasting total revenues for the quarter of $13.2 million (consensus is $12.1 million) and EPS of -$0.10 (consensus is -$0.12). Xoma remains significantly under-valued in our view. We maintain our Buy rating and have established a $5 target.

TECHNICAL>>
BULLISH
Probability - Intermediate trend bullish, Downtrend turned sideways, possible bottom.
Probability - 1 Day Price change extreme down, may pause/reverse
Probability - Oversold, odds favor long trades.
Probability - Short term typical pullback, pullback may start to slow.

UPTRADE QUALITY 90%, Excellent
Good trade quality is a combination of good profit, profit/loss ratio and target potential.

TARGET 1 Price: 3.13 Profit: 23.7% , for a typical rally.
Stop Limit/Trailing Stop Limit: 2.42 Loss: 4.3%
Profit/Loss Ratio: 5.5 : 1 - Excellent